Medicago: PhII avian flu vax trial successful

Canada's Medicago says the company's Phase II trial of its vaccine for avian flu elicited a solid immune response and was found to be safe and well tolerated. Notably, the vaccine was equally effective in older and younger subjects, which CEO Andy Sheldon could be a key selling point for the shot.

The vaccine is based on Medicago's manufacturing technologies and virus-like particles (VLPs), that allow the developer to rapidly produce more effective vaccines. Medicago is on the verge of opening a 90,000-square-foot facility in Research Triangle Park, NC to help manufacture VLP plant-based vaccine technology. The developer expects to have commercial capacity by this fall.

"...[W]e believe these results further support the effectiveness of our rapid plant-based vaccine platform and the development of our seasonal flu vaccine candidate which we intend to proceed with a U.S. clinical trial in the second half of the year," noted Sheldon in a release.

- here's Medicago's release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.